Life-Science Tools & Sequencing

Charles River Laboratories International unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools to shorten biologics and advanced therapy cell bank lead times for biopharma clients. The platform cuts cell bank production time by 40% and combines rapid microbiological methods with NGS characterization, including the iDTECT NGS platform, to support regulatory readiness. Charles River says the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The company, a US life sciences group with a market cap of about $13.1b, positions the offering for time-sensitive programs where delays are costly. Investors will watch for booked projects using the iDTECT NGS platform, client mix in advanced therapies, and whether the services appear in updated segment revenue breakdowns.

IP Group PLC reported that its net asset value exceeded GBP1 billion at the end of H1 2026, with NAV per share rising about 3% to 114p and reaching roughly 117p as of 11 September 2026. The company generated GBP69 million in cash proceeds during the half, up from GBP30 million a year earlier, plus GBP17 million after the period, bringing year-to-date proceeds to about GBP86 million and total proceeds since 2025 to GBP154 million, more than halfway toward its GBP250 million target by the end of 2027. Gross cash stood at GBP239 million at period end, while the portfolio was valued at roughly GBP900 million, or about 103p per share, with the top five assets accounting for about 50p per share. The Pfizer royalty interest rose GBP27 million to just over GBP150 million, and Oxford Nanopore posted GBP117 million in revenue, about 12% growth at constant currency, with gross margin up 400 basis points to 62% and its adjusted EBITDA loss more than halved to just over GBP22 million. Profit for the period was GBP31 million, effectively converted into cash, and about GBP50 million of proceeds is available for shareholder returns under the capital allocation policy.

Twist Bioscience announced on 16 September 2026 an agreement with Lilly TuneLab under which Twist will provide antibody characterization data services using preferred Twist protocols to generate high-quality wet lab data that feed Lilly's AI/ML drug discovery models. The collaboration plugs Twist's DNA and antibody capabilities into Lilly's AI-driven discovery ecosystem, potentially deepening its role in data-rich, AI-enhanced antibody development workflows across the biopharma industry. The deal follows Twist's US$300,000,000 follow-on equity raise in August 2026, a pairing that highlights a company still funding growth externally while positioning itself as a preferred data and DNA supplier to big pharma and AI drug discovery partners. Twist's narrative projects $753.3 million in revenue and $127.9 million in earnings by 2029, yielding a $105.30 fair value, a 26% downside to its current price, while some of the most optimistic analysts already expected revenue of about US$715,300,000 and earnings of roughly US$128,500,000 by 2029. The agreement may reinforce that bullish view on AI-driven demand, though it does not by itself resolve the near-term issue of achieving a credible path toward breakeven or reduce dependence on a concentrated set of large NGS customers.

S&P Dow Jones Indices announced on September 4, 2026, that Bloom Energy and Illumina are joining the S&P 500 benchmark, with the changes taking effect before trading opens on September 21, 2026, replacing Molson Coors, The Trade Desk, and Builders FirstSource. Bloom Energy arrives after product revenue jumped 215% last quarter on hyperscaler demand for onsite fuel-cell capacity, and management raised full-year revenue guidance to $3.9 billion to $4.2 billion. Illumina returns to the index with second-quarter revenue up 9% and raised EPS guidance of $5.30 to $5.40, though management flagged ongoing China and tariff headwinds. The swap barely moves returns for the Vanguard S&P 500 ETF, since new S&P 500 entrants typically begin well under a tenth of a percent of the index, while Vanguard's June 30, 2026 factsheet showed 38% of the fund in its ten largest holdings, including 8% in NVIDIA alone. The composition shift tilts the index toward growth at the margin, with Bloom carrying a beta of 3.81 and a forward P/E of 57x and Illumina at a forward P/E of 34x, while the departing Molson Coors trades at 7x forward earnings with a 4.9% dividend yield and Builders FirstSource at 14x.

Twist Bioscience and Ginkgo Bioworks traded higher on Wednesday after each announced agreements with Lilly TuneLab, a collaborative drug discovery platform established by Eli Lilly. Under its agreement, Twist Bioscience said it will provide antibody characterization data services to TuneLab companies accessing AI and machine learning drug discovery models trained on Lilly-owned research data. CEO Emily Leproust said Twist has the scale and high-throughput capabilities to generate consistent and reliable antibody characterization data these models need to be trained on. Ginkgo Bioworks, through its Ginkgo Datapoints offering, will provide discovery data generation services to TuneLab users. John Androsavich, General Manager at Ginkgo Datapoints, said layering on Ginkgo's ability to quickly generate high-quality, AI-ready datasets at any scale should let TuneLab participants close the loop between digital design and biological reality faster than ever before.

Twist Bioscience Corporation announced an agreement with Lilly TuneLab, the collaborative AI/ML drug discovery platform created by Eli Lilly and Company. Under the deal, Twist will serve as a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab users will be able to order antibody services from Twist using TuneLab preferred Twist protocols to generate high-quality wet lab data, connecting experimental data with AI-enabled discovery. Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, said the company has the scale and high-throughput capabilities to generate the consistent, reliable antibody characterization data these models need to be trained on. Lilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D.

The global nucleic acid isolation and purification market is projected to grow from USD 5.41 billion in 2026 to USD 10.52 billion by 2035, a compound annual growth rate of 6.9%, according to a new report from ResearchAndMarkets.com. Growth is being driven by demand for molecular diagnostics, next-generation sequencing, personalized medicine, genomics research and advanced drug discovery, with magnetic bead-based purification, automated extraction platforms and microfluidic systems improving processing speed and throughput. Approximately 370 companies currently offer nucleic acid isolation and purification products worldwide, with nearly 45% based in the Asia-Pacific region, and kits account for approximately 65% of the market. North America holds more than 40% of the global market, while the United States alone is expected to account for approximately 30% and expand at a CAGR of 6.8% through 2035. The report profiles key players including Roche, Promega, Macherey-Nagel, Bio-Rad, Danaher, Merck KGaA, Norgen Biotek, Perkin Elmer, Qiagen and Thermo Fisher Scientific.

Mayo Clinic and Thermo Fisher Scientific have launched Precure, LLC, a Mayo Clinic-controlled company that will build one of the world's leading biomedical datasets to identify signs of disease before symptoms appear. Mayo Clinic will serve as majority owner and Thermo Fisher joins as minority owner of the venture, which will generate molecular data from one million biospecimens linked with longitudinal clinical information collected over several years. The effort integrates proteomic, genomic and clinical data, with Thermo Fisher contributing its Olink Explore HT proteomics platform and Thermo Scientific Orbitrap Mass Spectrometry, kits and reagents. Precure, LLC complements Precure Research, Mayo Clinic's investigator-led scientific effort, by providing the scale, infrastructure and collaborations needed to generate population-scale molecular data and translate discoveries into new diagnostics, therapeutics and other healthcare solutions. Mayo Clinic said any financial returns from its involvement would be reinvested in its nonprofit mission of patient care, research and education.

Bangkok Genomics Innovation Public Company Limited, or BKGI, reported total revenue of 386.73 million baht for 2025, an increase of 40.86 million baht, or 11.81%, from the previous year, driven by revenue from sales of laboratory products, which came in at 111.87 million baht, up 37.96%, while service revenue rose 4.34%, amid competition and changes in reimbursement policy for prenatal chromosomal abnormality screening services. Dr. Saowalak Dansakul, Chief Executive Officer of BKGI, said the company aims to drive its Genomics and Precision Medicine business in line with the policy of pushing Thailand toward becoming an international health hub, or Medical Hub, and with the trend toward preventive medicine. The company is preparing for opportunities in the Genomics Thailand Phase 2 project and is laying out a B2B business model in the Wellness and Longevity market to support clinics and partners with genetic testing products and genetic counseling personnel. For the second half of the year, the company expects support from the gradual recognition of revenue from sales of test reagents following delivery of Sequencing, or NGS, machines, as well as steady revenue from the Oncology services group reimbursed through benefits of the National Health Security Office, or NHSO. Meanwhile, data from the National Statistical Office indicates that in 2024 Thailand had 13.68 million people aged 60 and over, up from 11.63 million in 2020, a structural factor supporting the preventive health market.

Tempus AI announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years, with a long-term goal of reaching one million genomes. The company said the effort will create the first de-identified multimodal whole-genome sequencing dataset built around disease populations and patient outcomes and specifically optimized for AI-driven research. The new dataset will be integrated into Tempus' existing de-identified multimodal data environment, where researchers can access genomic information alongside clinical histories, imaging, pathology and patient outcomes, and analyze it through Tempus Lens without moving datasets between systems. Development is already underway and the initial dataset is available through Tempus' Early Adopter Program, with additional members onboarded in waves and general availability planned for mid-2027. Founder and CEO Eric Lefkofsky said adding whole genome data linked to longitudinal outcomes gives researchers a richer foundation to build AI models and ultimately improve patient care.

MarketsandMarkets projects the global MRI systems market will grow from USD 6.88 billion in 2026 to USD 9.68 billion by 2031, at a CAGR of 7.0%. Growth is driven by the rising prevalence of neurological and musculoskeletal disorders, an expanding geriatric population, increasing chronic diseases like cancer, and supportive regulatory and reimbursement policies. The closed MRI systems segment held the largest market share in 2025, as did the fixed/stationary design segment. Asia Pacific is experiencing rapid growth, particularly in China, India, and Southeast Asia. Key players include Siemens Healthineers, GE HealthCare, Philips, FUJIFILM, and Canon, with innovations focusing on AI-enabled workflows and helium-free systems.

A new report from ResearchAndMarkets.com forecasts the global research use recombinant protein market to grow from $1.11 billion in 2026 to $1.55 billion by 2031, at a compound annual growth rate of 7.0%. The market's expansion is driven by growing recombinant therapeutic pipelines, increased preclinical research in advanced therapies, and rising demand for recombinant proteins in tumor microenvironment studies. Among species, human recombinant proteins are expected to record the highest CAGR, while cytokines and chemokines are projected to lead the market in 2026. The United States is forecast to register the highest CAGR, supported by advanced biomedical research infrastructure and high adoption in drug discovery. Key players include Thermo Fisher Scientific, Bio-Techne, Merck KGaA, Danaher, and Revvity.

S&P Dow Jones Indices announced that Bloom Energy, Everpure, and Illumina will join the S&P 500 before trading begins Monday, September 21, replacing Molson Coors Beverage, Trade Desk, and Builders FirstSource. Bloom Energy, the largest incoming company with a market capitalization of $74 billion, supplies fuel-cell systems for data centers and industrial facilities, offering exposure to AI-driven power demand. Everpure provides data-storage systems and software, while Illumina makes gene-sequencing tools. All three stocks have gained at least 40% in 2026. Index funds and ETFs tracking the benchmark must buy the new constituents and sell the departing companies, potentially boosting volume and price moves near the effective date. A parallel S&P 100 reshuffle will add Dell, Palo Alto Networks, Arista Networks, and SanDisk, while removing Honeywell Aerospace, Nike, Simon Property Group, and Colgate-Palmolive.

The global cardiovascular ultrasound system market is projected to grow from $1.73 billion in 2025 to $1.89 billion in 2026, a compound annual growth rate of 9.8%, and is forecast to reach $2.77 billion by 2030 at a CAGR of 10%, according to a new report from ResearchAndMarkets.com. Growth is driven by rising cardiovascular disease prevalence, demand for early non-invasive diagnostics, and adoption of AI-assisted imaging and portable devices. North America was the largest market in 2025, while Asia-Pacific is expected to be the fastest-growing region. Key developments include Royal Philips' August 2025 launch of Transcend Plus for its EPIQ CVx and Affiniti CVx systems, featuring FDA-cleared AI, and Philips' May 2023 acquisition of DiA Imaging Analysis for approximately $100 million to bolster AI-driven cardiac analysis. The report profiles major players including GE HealthCare, Siemens Healthineers, and Koninklijke Philips.

GE HealthCare announced on August 31 that its Photonova Spectra photon-counting CT scanner received CE Mark approval, enabling sales across Europe and other regions recognizing the certification, following US FDA 510(k) clearance and Japanese regulatory approval in March 2026. The scanner, built on proprietary Deep Silicon detector technology, rotates in 0.23 seconds, covers 80 millimeters per rotation, and processes up to 50 times more data than conventional CT scanners, with NVIDIA's accelerated computing platform to maintain workflow speed. The company is partnering with UZ Brussel and Rigshospitalet for clinical research in cardiology, oncology, and musculoskeletal imaging. In the quarter ended June 30, GE HealthCare posted record organic orders growth of 11.1%, a book-to-bill ratio of 1.15, and a backlog of $23.9 billion, with revenue reaching $5.3 billion, up 5.7%. However, Patient Care Solutions, a segment covering patient monitoring, saw revenue drop 13.3% and swung to a segment EBIT loss of $26 million, prompting a review of strategic options for that unit. Company-wide adjusted EBIT margin slipped 40 basis points to 14.2%, and management reaffirmed full-year guidance for organic revenue growth of 3.0% to 4.0% and adjusted earnings per share of $4.80 to $5.00.

Agilent Technologies raised its full-year fiscal 2026 earnings per share guidance to $6.18 to $6.21, excluding the net benefit of tariff refunds, earnings per share of $6.12 to $6.15 are now expected, after reporting third-quarter revenue of $1.88 billion, up 7.3% on a core basis, with China growing 9% despite minimal stimulus benefit. The company now expects full-year revenue of $7.49 billion to $7.51 billion, implying fourth-quarter revenue of $1.98 billion to $2 billion and EPS of $1.71 to $1.74. CEO Padraig McDonnell cited strong pharma growth of 12%, advanced therapeutics growth of nearly 30%, and competitive wins in China, while CFO Adam Elinoff noted Biocare contributed $10 million in Q3 and about $23 million in Q4 guidance. Management also highlighted a reshoring opportunity sized at about $1 billion through 2030, with orders secured from five of the top ten pharma companies, and expects revenue from reshoring to begin in fiscal 2027.

Masimo, a Danaher company, announced FDA 510(k) clearance for its Root with LiDCO hemodynamic monitoring solution, including the Masimo LiDCO sensor, enabling continuous monitoring of oxygen delivery. The system combines continuous noninvasive hemoglobin, Masimo SET oxygen saturation, and cardiac output to provide a beat-to-beat view of oxygen being delivered to tissue. Dr. Basil Matta, Chief Medical Officer at Masimo, said the technology gives clinicians a continuous view of oxygen delivery and helps them better understand changes in a patient's oxygen supply as they occur. Clinical studies cited by the company showed preoperative optimization of oxygen delivery reduced mortality from 17% to 3% in one trial, and another trial demonstrated a 75% reduction in 28-day mortality when targeting oxygen delivery greater than 600 mL/min/m².

Merck and Moderna announced positive topline Phase 3 results for their individualized cancer vaccine intismeran autogene in resected melanoma, beating Keytruda alone on recurrence-free survival, though no specific efficacy numbers have been released yet. The news lifted several biotech names, with BioNTech surging 21.6% on read-across excitement and Illumina rising 15.6% to $223.22 because its NovaSeq X sequencers are required for every individualized neoantigen dose manufactured. Pacific Biosciences gained 5.8% to $1.28, Repligen traded at $181.62 after reporting second-quarter revenue of $204 million with 13% organic growth, and Danaher saw mid-teens bioprocessing order growth in the second quarter. Leerink Partners analyst Daina Graybosch called the market reaction overly optimistic but still raised her 2032 intismeran forecast to $1.4 billion, while Morningstar projects $16.8 billion by 2035.

Abbott Laboratories and Thermo Fisher Scientific both reported encouraging quarterly results, with Abbott's diagnostics segment sales rising 42% to $3.09 billion in fiscal Q2, surpassing the estimate of $3.02 billion. Abbott reaffirmed its full-year comparable sales growth guidance of 6.5% to 7.5%, while Thermo Fisher's organic revenue increased 5%, signaling a potential recovery in life sciences spending. Thermo Fisher's management highlighted improving customer activity across pharmaceutical and biotechnology markets, and its Analytical Instruments business returned to growth after nearly two years of weak demand. Abbott's diversified portfolio across diagnostics, medical devices, and nutrition provides resilience, while Thermo Fisher's outlook depends more heavily on continued recovery in pharmaceutical and biotechnology spending.

10x Genomics reported second-quarter revenue of $151 million, boosted by a $1.6 million settlement payment from Takara, while booked orders for its new Atera instrument platform already exceeded the roughly 40 units planned for all of 2026. Excluding the settlement, revenue grew just 3% year-over-year to $149.4 million, with consumables up 7% and spatial consumables climbing 16% on Xenium strength. Total instrument revenue fell 47% as customers delayed purchases of older systems, and management guided for a sequential revenue step down in the third quarter before a fourth-quarter jump. The company raised full-year revenue guidance to $610 million to $630 million, and cash and marketable securities rose to $552 million. 10x also acquired Proteintech Genomics and announced research partnerships with Cleveland Clinic and Lausanne University Hospital.

Thermo Fisher Scientific received FDA 510(k) clearance for its EXENT Solution, an automated mass spectrometry platform for multiple myeloma. The clearance was highlighted at the ADLM conference in Anaheim in late July 2026, alongside the EliA CTD 13 Screen for autoimmune connective tissue diseases. The EXENT clearance strengthens Thermo Fisher's specialty diagnostics presence in oncology and supports its strategy of linking high-complexity diagnostics with integrated software and standardized clinical decision support. The company's investment narrative projects $54.1 billion in revenue and $9.5 billion in earnings by 2029, requiring 6.2% annual revenue growth from a current earnings base of $6.8 billion.

The global bioinformatics market is projected to grow from $20.9 billion in 2024 to $43.5 billion by 2030, a compound annual growth rate of 13.1%, according to a new report by BCC Research. North America holds a 47.7% share, driven by institutional investment in genomic research and a mature biopharma ecosystem. Key drivers include AI and cloud computing integration, rising demand for personalized medicine and oncology applications, and emerging technologies such as long-read sequencing and single-cell multiomics. Major companies in the space include Illumina, Thermo Fisher Scientific, Agilent Technologies, and Dassault Systèmes.

Merck KGaA raised its full-year 2026 guidance after reporting accelerating organic sales and earnings growth in the second quarter, driven by its Life Science and Electronics segments. Group organic sales rose 4.1 percent, while EBITDA pre increased 9.3 percent organically to 1.6 billion euros. The company now expects 2026 organic sales growth of 1 to 3 percent, EBITDA pre of 5.9 to 6.3 billion euros, and EPS pre of 7.90 to 8.60 euros. Life Science organic sales grew 8 percent, led by a 15 percent increase in Process Solutions, and Electronics organic sales jumped 11.7 percent on strong semiconductor demand for AI and data-center applications. Healthcare organic sales declined 3.4 percent due to U.S. competition and the loss of Mavenclad exclusivity, though rare-disease products contributed positively. Merck also confirmed it remains on track to acquire Bio-Techne by the end of 2026 or early 2027, expecting about 140 million euros in annual cost synergies by the third year after closing.

Diamond Hill Capital's Mid Cap Strategy highlighted Illumina's strong clinical momentum in its second-quarter 2026 investor letter. The biotechnology company, a leading producer of next-generation sequencing systems, saw its shares rise after reporting better-than-expected clinical growth, while competitor Roche's comparable product launch appeared underwhelming. Illumina closed at $203.01 per share on August 4, 2026, with a one-month return of 6.92% and a 52-week gain of 112.65%. The company has a market capitalization of $30.65 billion and a 52-week trading range between $88.00 and $207.00.

PacBio announced the upcoming release of SPRQ-Nx chemistry and a software update for its Vega benchtop sequencing system, increasing HiFi data output from 60 Gb to 90 Gb per run while lowering the U.S. list price from $1,100 to $995. The higher output and lower price reduce cost per gigabase by approximately 40%, and the update introduces two-hour and four-hour run options alongside new 5hmC, 5mC, and 6mA methylation callers that bring Vega’s multiomic capabilities in line with the high-throughput Revio system. The software also adds user login and audit-tracking features to support 21 CFR Part 11 compliance, and DNA input requirements drop from 2 µg to as low as 500 ng, enabling up to 96-sample multiplexing with PureTarget panels. PacBio plans to ship the new chemistry and make the software available for download by the end of the month.

GeneDx Holdings Corp. reaffirmed its full-year 2026 revenue guidance of $475 million to $490 million and said it expects meaningful improvements in its collection rate beginning in the fourth quarter. The company reported second-quarter total revenue of $114.4 million, up 11% year-over-year, with exome and genome revenues reaching $100.3 million on record test volume of 30,785, a 32% increase. GeneDx returned to profitability one quarter earlier than expected, posting adjusted net income of $0.4 million, and completed $25 million in annual cost actions. The blended average reimbursement rate was $3,258 per test, roughly flat quarter-over-quarter, while the outpatient genome collection rate stood at approximately 32%, unchanged from the first quarter but down from 43% a year earlier. Management highlighted a major commercial coverage expansion by Carelon that lifted genome coverage from 47% to 87%, though the financial benefit is expected to materialize more fully in 2027 due to coverage-leads-and-payment-lags dynamics. The company also strengthened its balance sheet with a $50 million expansion of its debt facility and a concurrent equity investment from Blackstone Life Sciences, bringing pro forma liquidity to about $188 million as of June 30, 2026.

Agilent Technologies has received European certification for its PD-L1 IHC 22C3 pharmDx test as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma, enabling pathologists to identify patients who may benefit from Merck's Keytruda. This marks the eighth CE-marked indication for the 22C3 assay in the EU, following an FDA approval of a related PD-L1 test for esophageal and gastric cancers nine days earlier. The approval extends the reach of an existing assay already used in labs worldwide, supporting Agilent's strategy of compounding its diagnostics footprint through incremental label expansions rather than relying on a single blockbuster product. The company also recently closed its acquisition of Biocare Medical to deepen its clinical pathology presence. However, Agilent faces competition from Danaher's Leica Biosystems, which is strengthening its own pathology pipeline with the planned acquisition of StatLab Medical Products, and the broader life sciences tools sector remains sensitive to growth outlook revisions, as seen when Danaher's stock fell 14% after trimming its core revenue growth forecast.

Illumina lifted its full-year 2026 revenue guidance to a range of $4.60 billion to $4.64 billion, up from the prior $4.52 billion to $4.62 billion set in February, driven by stronger clinical sequencing demand and higher consumables volume. The company reported second-quarter revenue of $1,159 million, up from $1,059 million a year earlier, while net income eased to $207 million from $235 million and diluted earnings per share from continuing operations slipped to $1.35 from $1.49. Illumina also guided third-quarter revenue of $1.14 billion to $1.16 billion. The raised outlook underscores how clinical sequencing and consumables are reshaping the growth mix, even as softer net income and earnings per share keep near-term execution and margin trends in focus.

Eli Lilly has joined Illumina's Billion Cell Atlas alliance as a foundational participant, gaining access to what is described as the world's largest genome-wide genetic perturbation dataset. The alliance is sequencing hundreds of millions of cells across more than 200 disease-relevant cell lines using CRISPR to map disease mechanisms and find new drug targets. Eli Lilly's participation positions it alongside peers such as AstraZeneca and Merck in building core infrastructure for AI-powered drug discovery, potentially broadening its pipeline beyond its current heavy reliance on GLP-1 obesity and diabetes drugs. The collaboration is seen as a long-term capability move rather than a near-term earnings event, with investors watching for how insights from the atlas translate into faster drug progression in areas like neuroscience and oncology.

Alamar Biosciences has launched the NULISAseq Immune 340 Panel, a multiplex immunoassay that measures approximately 340 immune-related proteins from a single sample. The panel expands on the company's NULISAseq Inflammation Panel 250 and is designed to capture low-abundance targets such as cytokines, chemokines, and immune checkpoint inhibitors that are often undetectable by standard platforms. Alamar's founder and CEO Dr. Yuling Luo stated that the panel provides an unprecedented view of immune system activity, which could accelerate biomarker discovery and the development of new therapies and diagnostics. Bailin Zhang, Head of Exploratory Biomarkers in Translational Medicine at Sanofi, noted that the panel's combination of breadth and sensitivity opens new possibilities for biomarker discovery and patient stratification by enabling simultaneous measurement of proteins related to immune mechanisms of action, drug resistance, and toxicity.

The global precision diagnostics and medicine market is projected to grow from approximately USD 147.23 billion in 2025 to around USD 345.75 billion by 2035, at a compound annual growth rate of 8.91 percent during the forecast period from 2026 to 2035, according to a report by Custom Market Insights. The market is expected to reach USD 159.66 billion in 2026. Key players include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN N.V., Agilent Technologies Inc., Danaher Corporation, Abbott Laboratories, Siemens Healthineers AG, Bio-Rad Laboratories Inc., Exact Sciences Corporation, Guardant Health Inc., Natera Inc., Myriad Genetics Inc., Foundation Medicine Inc., and NeoGenomics Laboratories Inc. Growth is driven by increasing adoption of precision medicine, advancements in next-generation sequencing and AI, and rising prevalence of cancer and chronic diseases. North America held the largest market share, while Asia Pacific is expected to be the fastest-growing region.

The U.S. Food and Drug Administration has approved Freenome's SimpleScreen CRC, a blood-based screening test for colorectal cancer in adults 45 and older at average risk, with Abbott set to exclusively commercialize the test in the U.S. this fall. The approval triggers a $100 million milestone payment from Abbott to Freenome under their August 2025 commercial agreement. In the PREEMPT CRC study, the largest prospective validation study for a blood-based colorectal cancer screening test, SimpleScreen CRC demonstrated 81.1% sensitivity for colorectal cancer and 90.4% specificity for advanced colorectal neoplasia. The test meets Medicare coverage criteria and is expected to be incorporated into American Cancer Society guidelines by name, expanding access for up to 60 million Americans who are overdue for screening. Freenome plans to include SimpleScreen CRC in its broader SimpleScreen portfolio while advancing additional single- and multi-cancer tests on the same multiomics platform.

President Donald Trump announced phased tariffs on generic drug imports, starting with zero tariffs for two years from August 1, then rising to 100% in August 2028 and 200% a year later, to push production onshore. Novo Nordisk sued Eli Lilly over ads comparing their GLP-1 weight-loss drugs, alleging misleading efficacy claims. Molina Healthcare shares fell about 11% despite beating second-quarter estimates, as its medical care ratio reached 92.2%. Repligen agreed to acquire BioLife Solutions for about $1.5 billion in a stock-and-cash deal. Roche shares jumped roughly 5% after the company reiterated its 2026 outlook, while Thermo Fisher Scientific raised its full-year guidance following better-than-expected second-quarter results.

Danaher shares may be undervalued by about 16% relative to a fair value estimate of $228.61, according to a Simply Wall St analysis, even after the stock fell 16.9% year to date. The company recently issued third quarter 2026 revenue guidance of 2% to 3% growth and detailed share repurchases alongside its latest quarterly earnings. The fair value estimate assumes mid-single-digit revenue expansion, faster earnings growth, and a richer margin mix driven by life sciences and diagnostics, including AI-assisted diagnostic solutions and support for in vivo CRISPR therapies. However, the narrative also depends on bioprocessing recovery and China, where policy shifts and lumpy consumables demand could unsettle those assumptions.

Thermo Fisher reported second-quarter 2026 revenue of $11.99 billion, beating analyst estimates of $11.72 billion and representing 10.5% year-on-year growth. Adjusted earnings per share came in at $6.03, surpassing the consensus estimate of $5.71. CEO Marc Casper highlighted broad-based momentum across pharmaceutical, biotech, industrial, and diagnostics markets, with biotech recovery translating into revenue gains. New product launches, including next-generation Orbitrap mass spectrometers and AI-driven software, contributed to market share gains. The company also benefited from the integration of recent acquisitions Clario and filtration and separation businesses, while planning the divestiture of its microbiology business to sharpen focus on higher-growth areas.

Niki BioSolutions has entered an agreement to provide APOE genotyping services for Progressive Medical Research to support its clinical and translational research programs. The testing will be conducted through Niki BioSolutions' wholly-owned subsidiary DiamiR Biosciences, using its CAP-accredited and New York State CLEP-approved laboratory platform. The collaboration aims to generate genetic insights for Alzheimer's disease research by identifying APOE gene variants linked to the condition, cardiovascular health, and lipid metabolism. Niki BioSolutions closed Thursday's regular trading at $8.58, down 4.56%, and was further down 0.70% at $8.52 in the overnight market.

The global cell culture market is projected to reach USD 58.42 billion by 2031, rising from an estimated USD 33.07 billion in 2026 at a compound annual growth rate of 12.1%. Biopharmaceutical production led applications in 2025, while sera, media and reagents dominated consumables. Asia-Pacific is expected to record the fastest growth through 2031. Key players include Thermo Fisher Scientific, Danaher, Sartorius, Merck and Corning.

Agilent Technologies has received European Union certification for its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for treatment with Merck's KEYTRUDA. The approval is based on the KEYNOTE-B96/ENGOT-ov65 clinical trial and marks the eighth CE-marked indication for this assay in the EU. The test enables pathologists to assess PD-L1 expression in these tumor types, supporting treatment decisions in the platinum-resistant setting where options remain limited. Agilent developed the assay in partnership with Merck, and it is already indicated for several other cancers including non-small cell lung cancer and triple-negative breast cancer.